Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Primary result · Investigator-reported hyperkalaemia or initiation of potassium bindersResult — go to the resultHazard ratio 0.78 95% CI 0.64–0.95Authors' conclusion
Among patients treated with renin-angiotensin-aldosterone system inhibitors, SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in people with T2DM and CKD without increasing the risk of hypokalaemia.
Study context
- Population
- Participants with T2DM and chronic kidney disease (CKD) (99.9% on renin-angiotensin system blockade)
- Participants
- 4,401 participants
- Comparison
- Canagliflozin vs placebo
- Primary endpoint
- Time to investigator-reported hyperkalaemia or initiation of potassium binders
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Investigator-reported hyperkalaemia or initiation of potassium binders
Hazard ratio
0.78
95% CI 0.64–0.95
P = 0.014
By group
Canagliflozin vs Placebo
HR 0.78 (95% CI 0.64–0.95); P = 0.014
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Laboratory-determined hyperkalaemia (serum potassium ≥6.0 mmol/L) | 0.77 (0.61–0.98) | P = 0.031 | |
| 0.512Hazard ratio (log scale) |
Mean serum potassium over time
- Mean serum potassium over time similar with canagliflozin and placebo
Safety
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Laboratory-determined hypokalaemia (serum potassium <3.5 mmol/L) | 0.92 (0.71–1.20) | P = 0.53 | |
| 0.512Hazard ratio (log scale) |
Original publication
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. Published 23 August 2021. doi:10.
Summarised from the published abstract; every number is checked against it